Print page Share page

Our pipeline currently centers on two promising internally developed compounds: Iclusig (ponatinib) and AP26113.

 

Each was discovered by our own people. Each targets proven pathways to disrupting cancer growth. Each is being explored in multiple indications, chosen for the highest likelihood of success and potential for patient impact.

Our Pipeline

PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED (U.S. and EU)
Ponatinib*
CML, Ph+ ALL (refractory)
CML, Ph+ ALL (Japanese patients)
Gastrointestinal stromal tumors (KIT)
Lung cancer (FGFR)
Lung cancer (RET)
AML (FLT3)
Ph+ ALL (with chemo, 1st, 2nd line)
Medullary thyroid cancer (RET)
 
AP26113
Non-small cell lung cancer (ALK)

* Includes investigator-sponsored trials.
** In some trials, enrollment of new patients is on hold.

Iclusig: Click here for full U.S. prescribing information and Medication Guide (PDF), including Boxed Warning.

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue